NCT01750580View on ClinicalTrials.gov

Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
CANCER, NOS
Interventions
DRUG

Lirilumab

DRUG

Ipilimumab

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Ctr, New York

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

37203

Sarah Cannon Research Institute, Nashville

43210

The Ohio State University, Columbus

55455

University Of Minnesota, Minneapolis

02215

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY